Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Zacks News
Top Medical Stocks to Buy for Growth & Performance
by Shaun Pruitt
The medical sector is crawling with opportunity as indicated in its representation on the Zacks Rank #1 (Strong Buy) list.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -59.62% and 0.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Neurocrine (NBIX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Neurocrine (NBIX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ahead of Neurocrine (NBIX) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Neurocrine (NBIX) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMLX vs. NBIX: Which Stock Is the Better Value Option?
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Neurocrine (NBIX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Neurocrine (NBIX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Neurocrine (NBIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Neurocrine (NBIX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Neurocrine (NBIX) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
by Zacks Equity Research
Neurocrine (NBIX) delivered earnings and revenue surprises of -9.89% and 4.01%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Can Q3 GDP Excite Investors?
by John Blank
The recession bears will never go away. The bulls can take advantage of that.
Analysts Estimate United Therapeutics (UTHR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
United Therapeutics (UTHR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BEAM to Reprioritize Portfolio, Slash Jobs, Shares Tank
by Zacks Equity Research
BEAM announces a restructuring and portfolio reprioritization plan to focus on genome-editing candidate, BEAM-101. The company is set to reduce its workforce by almost 20%. Shares fall.
Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up
by Zacks Equity Research
Lisata (LSTA) shares rise 6.6% after its lead candidate, LSTA1, receives orphan drug designation from the European Commission for treating pancreatic cancer.